IMIQUIMOD cream

Valsts: Amerikas Savienotās Valstis

Valoda: angļu

Klimata pārmaiņas: NLM (National Library of Medicine)

Aktīvā sastāvdaļa:

Imiquimod (UNII: P1QW714R7M) (Imiquimod - UNII:P1QW714R7M)

Pieejams no:

Taro Pharmaceutical Industries Ltd.

SNN (starptautisko nepatentēto nosaukumu):

Imiquimod

Kompozīcija:

Imiquimod 50 mg in 1 g

Ievadīšanas:

TOPICAL

Receptes veids:

PRESCRIPTION DRUG

Ārstēšanas norādes:

Imiquimod Cream is indicated for the topical treatment of clinically typical, nonhyperkeratotic, nonhypertrophic actinic keratoses on the face or scalp in immunocompetent adults. Imiquimod Cream is indicated for the treatment of external genital and perianal warts/condyloma acuminata in patients 12 years or older. Imiquimod Cream has been evaluated in children ages 2 to 12 years with molluscum contagiosum and these studies failed to demonstrate efficacy. [see Use in Specific Populations (8.4)]. The safety and efficacy of Imiquimod Cream in immunosuppressed patients have not been established. Imiquimod Cream should be used with caution in patients with pre-existing autoimmune conditions. The efficacy and safety of Imiquimod Cream have not been established for patients with Basal Cell Nevus Syndrome or Xeroderma Pigmentosum. None. Pregnancy Category C: Note: The Maximum Recommended Human Dose (MRHD) was set at 2 packets per treatment of Imiquimod Cream (25 mg imiquimod) for the animal multiple of human exposure

Produktu pārskats:

Imiquimod Cream, 5%, is supplied in single-use packets which contain 250 mg of the cream: Box of 24 single-use packets – NDC 51672-4145-6 Discard unused packet. Store at 4° - 25°C (39° - 77°F) Avoid freezing. Keep out of reach of children.

Autorizācija statuss:

Abbreviated New Drug Application

Produkta apraksts

IMIQUIMOD- IMIQUIMOD CREAM
TARO PHARMACEUTICAL INDUSTRIES LTD.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
IMIQUIMOD SAFELY AND EFFECTIVELY. SEE FULL
PRESCRIBING INFORMATION FOR IMIQUIMOD.
IMIQUIMOD CREAM, 5%
FOR TOPICAL USE ONLY
INITIAL U.S. APPROVAL: 1997
INDICATIONS AND USAGE
Imiquimod Cream is indicated for the topical treatment of:
Clinically typical, nonhyperkeratotic, nonhypertrophic actinic
keratoses (AK) on the face or scalp in immunocompetent
adults (1.1)
External genital and perianal warts/condyloma acuminata in patients 12
years old or older (1.3)
Limitations of Use: Efficacy was not demonstrated for molluscum
contagiosum in children aged 2-12 (1.4, 8.4)
DOSAGE AND ADMINISTRATION
Imiquimod Cream is not for oral, ophthalmic, or intravaginal use.(2)
Actinic keratosis: 2 times per week for a full 16 weeks (2.1)
External genital warts (EGW): 3 times per week until total clearance
or a maximum of 16 weeks (2.3)
DOSAGE FORMS AND STRENGTHS
Imiquimod Cream, 5%, is supplied in single-use packets (24 per box),
each of which contains 250 mg of the cream,
equivalent to 12.5 mg of imiquimod. (3)
CONTRAINDICATIONS
None (4)
WARNINGS AND PRECAUTIONS
Intense local inflammatory reactions can occur (e.g., skin weeping,
erosion). Dosing interruption may be required (2,
5.1, 6)
Severe local inflammatory reactions of the female external genitalia
can lead to severe vulvar swelling. Severe vulvar
swelling can lead to urinary retention; dosing should be interrupted
or discontinued.
Flu-like systemic signs and symptoms including malaise, fever, nausea,
myalgias and rigors may occur. Dosing
interruption may be required (2, 5.2, 6)
Avoid exposure to sunlight and sunlamps. Wear sunscreen daily (5.3).
Safety and efficacy have not been established for repeat courses of
treatment to the same area for AK. (5.4)
Treatment of urethral, intra-vaginal, cervical, rectal or intra-anal
viral disease is not recommended. (5.6)
Safety and efficacy in immunosuppressed patie